SCHEMBL5954445

SCHEMBL5954445

CC1C(=O)N(c2ccccc2)C(=S)N1c1ccc(Cc2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.45
MEN1 O00255 4/20 0.45
MAPT P10636 4/20 0.45
ALDH1A1 P00352 3/20 0.45
SMO Q99835 3/20 0.45
GAA P10253 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP3A4 P08684 1/20 0.42
KDM4E B2RXH2 1/20 0.39
FAAH O00519 1/20 0.39
MGLL Q99685 1/20 0.39
MAOA P21397 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.38
CYP2C9 P11712 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5955372 1.00 KMT2A (0.45) KMT2AMEN1MAPTALDH1A1SMO
SCHEMBL5954448 0.92 SMO (0.56) KMT2AMEN1MAPTALDH1A1SMO
SCHEMBL5954554 0.90 LTA4H (0.50) KMT2AMEN1MAPTALDH1A1SMO
SCHEMBL5955264 0.88 KMT2A (0.43) KMT2AMEN1MAPTALDH1A1SMO
SCHEMBL5955227 0.83 NPC1 (0.47) KMT2AMEN1MAPTALDH1A1SMO
SCHEMBL5955334 0.83 NPC1 (0.47) KMT2AMEN1MAPTALDH1A1SMO
SCHEMBL5954387 0.81 MGLL (0.49) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL5955050 0.81 KMT2A (0.43) KMT2AMEN1MAPTALDH1A1SMO
SCHEMBL5954470 0.81 MGLL (0.49) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL5955377 0.81 KMT2A (0.43) KMT2AMEN1MAPTALDH1A1SMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LABORATOIRES FOURNIER S.A. (FR) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LIPC, CYP4F2, SLC5A2 KMT2A 1991/4885MEN1 3372/4885MAPT 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.